A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients With Vaso-Occlusive Crisis

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients With Vaso-Occlusive Crisis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 3 Feb 2020 to 17 Feb 2020.
    • 10 Nov 2017 Planned primary completion date changed from 3 Feb 2020 to 17 Feb 2020.
    • 10 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 13 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top